352 related articles for article (PubMed ID: 24262821)
1. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
[TBL] [Abstract][Full Text] [Related]
2. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.
Vargo JA; Ferris RL; Ohr J; Clump DA; Davis KS; Duvvuri U; Kim S; Johnson JT; Bauman JE; Gibson MK; Branstetter BF; Heron DE
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):480-8. PubMed ID: 25680594
[TBL] [Abstract][Full Text] [Related]
5. Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume.
Vargo JA; Heron DE; Ferris RL; Rwigema JC; Kalash R; Wegner RE; Ohr J; Burton S
Head Neck; 2014 Sep; 36(9):1349-55. PubMed ID: 24038398
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy: an attractive treatment modality for recurrent head and neck carcinoma. (Regarding Lartigau et al.: Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer).
Cacicedo J; Bilbao P
Radiother Oncol; 2014 Jun; 111(3):482-3. PubMed ID: 24631142
[No Abstract] [Full Text] [Related]
7. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
8. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer.
Vargo JA; Heron DE; Ferris RL; Rwigema JC; Wegner RE; Kalash R; Ohr J; Kubicek GJ; Burton S
Radiother Oncol; 2012 Jul; 104(1):91-5. PubMed ID: 22677037
[TBL] [Abstract][Full Text] [Related]
11. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
12. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.
Unger KR; Lominska CE; Deeken JF; Davidson BJ; Newkirk KA; Gagnon GJ; Hwang J; Slack RS; Noone AM; Harter KW
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1411-9. PubMed ID: 20056341
[TBL] [Abstract][Full Text] [Related]
13. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience.
Rwigema JC; Heron DE; Ferris RL; Gibson M; Quinn A; Yang Y; Ozhasoglu C; Burton S
Am J Clin Oncol; 2010 Jun; 33(3):286-93. PubMed ID: 19875950
[TBL] [Abstract][Full Text] [Related]
14. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
[TBL] [Abstract][Full Text] [Related]
16. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer.
Roh KW; Jang JS; Kim MS; Sun DI; Kim BS; Jung SL; Kang JH; Yoo EJ; Yoon SC; Jang HS; Chung SM; Kim YS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1348-55. PubMed ID: 19117695
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution.
Milanović D; Jeremić B; Grosu AL; Rücker G; Henke M
Strahlenther Onkol; 2013 Oct; 189(10):842-8. PubMed ID: 23861154
[TBL] [Abstract][Full Text] [Related]
18. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
[TBL] [Abstract][Full Text] [Related]
19. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
[TBL] [Abstract][Full Text] [Related]
20. [Reirradiation for recurrent or second primary head and neck cancers].
Mouttet-Audouard R; Gras L; Comet B; Lartigau E
Bull Cancer; 2011 Dec; 98(12):1477-88. PubMed ID: 22157636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
